Table 2.

Novel agents targeting PI3K signaling in cancer

Class	Inhibitor	Phase	Toxic effects	Reference
Pan‑PI3K inhibitors	GDC-0941	I	Neutropenia、Neuropsychiatric effects (confusion, depression, anxiety)、Hepatotoxicity、Diarrhea	254
	BKM-120	II	Hyperglycemia	255
	BAY-80-6946	Approved	Nausea High blood sugar	256
	XL-147	I	Rash	257
	PX-866	II	Diarrhea ALT/AST elevation	258
Isoform-selective PI3K inhibitors	BYL-719	I	Hyperglycemia	259
	GDC-0032	I	Rash、Diarrhea、Pneumonitis	206
	IPI-145	Approved	Hyperglycemia、Rash、Diarrhea、Hypertension	260
	SAR-260301	Preclinical	Nausea、Vomiting、Diarrhea	261
	MLN-1117	I	Nausea	262
Dual pan‑PI3K and mTOR inhibitors	BEZ-235	I/II	Fatigue/asthenia、Thrombocytopenia	263
	SF-1126	I/II	Hyperglycemia	264
	GDC-0980	I	Maculopapular　rash Symptomatic hyperglycemia	265
	PF-04691502	II	Fatigue Loss of appetite、Nausea、High blood sugar、Rash、Vomiting	266
	XL-765	I	Stomatitis	267
	GSK-2126458	I	Diarrhea	268
	PF-05212384	II	Fatigue	266
	GSK-1059615	Preclinical	Immunosuppression	269
	BGT-226	I/II	Diarrhea Nausea Loss of appetite Vomiting Fatigue	270